Research graph

Cited by

Admitted local publications that cite Prospective, randomized, placebo-controlled, multicenter, double-blind, parallel-group, registration field trial evaluating izenivetmab, a caninized anti-nerve growth factor monoclonal antibody, administered quarterly to dogs with naturally occurring osteoarthritis.